Ardelyx (MEX:ARDX) Cyclically Adjusted Revenue per Share: MXN16.34 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ARDX Ardelyx Inc MEX:ARDX
69 GF Score
Price MXN99.00
GF Value MXN217.64
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ardelyx Cyclically Adjusted Revenue per Share?

Ardelyx MEX:ARDX 69 Cyclically Adjusted Revenue per Share is MXN16.34 as of Mar. 2026. GuruFocus rates MEX:ARDX with a GF Score™ of 69/100 and a GF Value™ of MXN217.64 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ardelyx's adjusted revenue per share for the three months ended in Mar. 2026 was MXN6.929. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN16.34 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ardelyx's average Cyclically Adjusted Revenue Growth Rate was 4.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -20.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Ardelyx was -20.40% per year. The lowest was -20.40% per year. And the median was -20.40% per year.

As of today (2026-07-19), Ardelyx's current stock price is MXN99.00. Ardelyx's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN16.34. Ardelyx's Cyclically Adjusted PS Ratio of today is 6.06.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ardelyx was 10.79. The lowest was 0.82. And the median was 6.84.


Ardelyx  (MEX:ARDX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ardelyx's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=99.00/16.34
=6.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ardelyx was 10.79. The lowest was 0.82. And the median was 6.84.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ardelyx Cyclically Adjusted Revenue per Share Related Terms


Ardelyx Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ardelyx's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ardelyx Cyclically Adjusted Revenue per Share Chart

Ardelyx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 20.64 16.06 15.09

Ardelyx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.69 17.22 15.08 15.09 16.34

MEX:ARDX vs AVLN, INBX, JBIO: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Ardelyx's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ardelyx Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ardelyx's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ardelyx's Cyclically Adjusted PS Ratio falls into.


MEX:ARDX
69GF Score
Ardelyx Inc MEX:ARDX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ardelyx Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ardelyx's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=6.929/330.2130*330.2130
=6.929

Current CPI (Mar. 2026) = 330.2130.

Ardelyx Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 17.355 246.524 23.247
201803 0.886 249.554 1.172
201806 0.011 251.989 0.014
201809 0.052 252.439 0.068
201812 0.027 251.233 0.035
201903 0.000 254.202 0.000
201906 0.006 256.143 0.008
201909 0.947 256.759 1.218
201912 0.607 256.974 0.780
202003 0.320 258.115 0.409
202006 0.476 257.797 0.610
202009 0.671 260.280 0.851
202012 0.395 260.474 0.501
202103 1.384 264.877 1.725
202106 0.261 271.696 0.317
202109 0.232 274.310 0.279
202112 0.183 278.802 0.217
202203 0.071 287.504 0.082
202206 0.349 296.311 0.389
202209 0.607 296.808 0.675
202212 4.467 296.797 4.970
202303 0.990 301.836 1.083
202306 1.781 305.109 1.928
202309 4.310 307.789 4.624
202312 2.510 306.746 2.702
202403 3.277 312.332 3.465
202406 5.719 314.175 6.011
202409 8.200 315.301 8.588
202412 10.203 315.605 10.675
202503 6.354 319.799 6.561
202506 7.664 322.561 7.846
202509 8.366 324.800 8.505
202512 9.254 324.054 9.430
202603 6.929 330.213 6.929

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN16.34 mean?
Ardelyx (MEX:ARDX) has a Cyclically Adjusted Revenue per Share of MXN16.34 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ardelyx and its competitors.
Is Ardelyx's Cyclically Adjusted Revenue per Share too high?
Ardelyx's current Cyclically Adjusted Revenue per Share is MXN16.34. Overall, Ardelyx has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's Cyclically Adjusted Revenue per Share compare to AVLN and INBX?
Ardelyx's Cyclically Adjusted Revenue per Share of MXN16.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ardelyx and its competitors. Ardelyx's current Cyclically Adjusted Revenue per Share is MXN16.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (MEX:ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is MXN217.64, compared to a current price of MXN99.00 — trading 54.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN16.34. Ardelyx's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ardelyx (MEX:ARDX), the current Cyclically Adjusted Revenue per Share is MXN16.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ardelyx (MEX:ARDX) Overvalued in 2026?

Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued. The current stock price of MXN99.00 is trading 54.5% below its estimated GF Value™ of MXN217.64. GuruFocus considers Ardelyx to be Possible Value Trap.

Key valuation signals for MEX:ARDX:

  • Cyclically Adjusted Revenue per Share: MXN16.34
  • GF Value™: MXN217.64 vs. price of MXN99.00 (54.5% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the MEX:ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ardelyx Business Description

Other Exchanges ARDX:USA41X:Germany
Address 400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
69GF Score

Get the complete analysis for MEX:ARDX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN99.00
Price
MXN217.64
GF Value